Skip to content

Study · Not a test of the peptide alone · 2026

5 results

Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.

Shinde S, Kahles F, Vasileva-Metodiev S, Griffin R, Liu-Seifert H, Lebrec J, Xavier NA, Li R, Klise SR, Singh A, Aberle J

Diabetes, obesity & metabolism17 Sept 2026

PMID42750540 (opens in a new tab)DOI10.1111/dom.71322 (opens in a new tab)PepBankPUB-42750540
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Orforglipron.

  1. 01Computer modelNot a test of Orforglipron aloneIn silicoOther

    In risk models for adults with overweight or obesity, orforglipron lowered predicted diabetes risk more than placebo.

    In plain wordsIn computer risk models for trial participants, orforglipron lowered predicted diabetes risk more than placebo.

    Peptide
    Orforglipron
    Outcome
    DecreasePredicted type 2 diabetes risk
    Study

    humann: not reported in source

    Risk prediction engines applied to ATTAIN-1 data
    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Relative risk score change
    −48.6 to −59.4%
    orforglipron
    Relative risk score change
    −10.5%
    placebo

    Source sentences

    Summary
    At week 72, mean relative reduction from baseline (median baseline scores: 16.0%-17.3%) in T2D risk score was significantly greater with orforglipron than placebo (-48.6% to -59.4% vs. -10.5%; p < 0.0001; HR-range 0.43-0.55).
    2 context sentences
    Summary · context
    Participants received orforglipron 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks.
    Summary · context
    Changes in predicted risk from baseline to 72 weeks were assessed using three validated risk prediction engines: Cardiometabolic Disease Staging (T2D risk), Framingham (total CVD risk), and PREVENT (total CVD, ASCVD, and HF risk).

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  2. 02Computer modelNot a test of Orforglipron aloneIn silicoOther

    In risk models for adults with overweight or obesity, orforglipron lowered Framingham predicted total cardiovascular risk versus placebo.

    In plain wordsIn computer risk models for trial participants, orforglipron lowered predicted total cardiovascular risk versus placebo.

    Peptide
    Orforglipron
    Outcome
    DecreaseFramingham predicted total CVD risk
    Study

    humann: not reported in source

    Risk prediction engines applied to ATTAIN-1 data
    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Using Framingham, at week 72, orforglipron was associated with a significant decrease in mean absolute change in total CVD risk vs placebo (-0.6% to -1.00% vs. +0.6%; p < 0.0001; HR range: 0.82-0.87).
    2 context sentences
    Summary · context
    Participants received orforglipron 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks.
    Summary · context
    Changes in predicted risk from baseline to 72 weeks were assessed using three validated risk prediction engines: Cardiometabolic Disease Staging (T2D risk), Framingham (total CVD risk), and PREVENT (total CVD, ASCVD, and HF risk).

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  3. 03Computer modelNot a test of Orforglipron aloneIn silicoOther

    In risk models for adults with overweight or obesity, orforglipron lowered PREVENT predicted ASCVD risk versus placebo.

    In plain wordsIn computer risk models for trial participants, orforglipron lowered predicted atherosclerotic cardiovascular risk versus placebo.

    Peptide
    Orforglipron
    Outcome
    DecreasePREVENT predicted ASCVD risk
    Study

    humann: not reported in source

    Risk prediction engines applied to ATTAIN-1 data
    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Similarly, at week 72, orforglipron was associated with reduced predicted ASCVD, HF, and total CVD risks compared to placebo, assessed using PREVENT (p < 0.0001).
    2 context sentences
    Summary · context
    Participants received orforglipron 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks.
    Summary · context
    Changes in predicted risk from baseline to 72 weeks were assessed using three validated risk prediction engines: Cardiometabolic Disease Staging (T2D risk), Framingham (total CVD risk), and PREVENT (total CVD, ASCVD, and HF risk).

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  4. 04Computer modelNot a test of Orforglipron aloneIn silicoOther

    In risk models for adults with overweight or obesity, orforglipron lowered PREVENT predicted heart failure risk versus placebo.

    In plain wordsIn computer risk models for trial participants, orforglipron lowered predicted heart failure risk versus placebo.

    Peptide
    Orforglipron
    Outcome
    DecreasePREVENT predicted heart failure risk
    Study

    humann: not reported in source

    Risk prediction engines applied to ATTAIN-1 data
    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Similarly, at week 72, orforglipron was associated with reduced predicted ASCVD, HF, and total CVD risks compared to placebo, assessed using PREVENT (p < 0.0001).
    2 context sentences
    Summary · context
    Participants received orforglipron 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks.
    Summary · context
    Changes in predicted risk from baseline to 72 weeks were assessed using three validated risk prediction engines: Cardiometabolic Disease Staging (T2D risk), Framingham (total CVD risk), and PREVENT (total CVD, ASCVD, and HF risk).

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

  5. 05Computer modelNot a test of Orforglipron aloneIn silicoOther

    In risk models for adults with overweight or obesity, orforglipron lowered PREVENT predicted total cardiovascular risk versus placebo.

    In plain wordsIn computer risk models for trial participants, orforglipron lowered PREVENT predicted total cardiovascular risk versus placebo.

    Peptide
    Orforglipron
    Outcome
    DecreasePREVENT predicted total CVD risk
    Study

    humann: not reported in source

    Risk prediction engines applied to ATTAIN-1 data
    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular

    Source sentences

    Summary
    Similarly, at week 72, orforglipron was associated with reduced predicted ASCVD, HF, and total CVD risks compared to placebo, assessed using PREVENT (p < 0.0001).
    2 context sentences
    Summary · context
    Participants received orforglipron 5.5 mg, 9 mg, or 17.2 mg, or placebo for 72 weeks.
    Summary · context
    Changes in predicted risk from baseline to 72 weeks were assessed using three validated risk prediction engines: Cardiometabolic Disease Staging (T2D risk), Framingham (total CVD risk), and PREVENT (total CVD, ASCVD, and HF risk).

    In this study, Orforglipron was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Orforglipron.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 3Results postedNCT05869903

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Eli Lilly and Companyn = 3,1275 Jun 2023 to est. Oct 2027

Obesity · Overweight · Overweight or Obesity

Trial pageClinicalTrials.govUpdated 14 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.